{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:49:29Z","timestamp":1773420569036,"version":"3.50.1"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,5]]},"DOI":"10.4103\/0366-6999.172599","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T11:37:47Z","timestamp":1450957067000},"page":"81-87","source":"Crossref","is-referenced-by-count":4,"title":["Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease"],"prefix":"10.1097","volume":"129","author":[{"given":"Yan-Huan","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"R2-14-20210129","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2013.168118","article-title":"Prevalence and control of diabetes in Chinese adults","volume":"310","author":"Xu","year":"2013","journal-title":"JAMA"},{"key":"R3-14-20210129","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3949\/ccjm.76a.09054","article-title":"Managing diabetes in hemodialysis patients: Observations and recommendations","volume":"76","author":"Shrishrimal","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"R4-14-20210129","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ki.1997.260","article-title":"Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study","volume":"51","author":"Hunsicker","year":"1997","journal-title":"Kidney Int"},{"key":"R5-14-20210129","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0735-1097(99)00035-2","article-title":"The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics","volume":"33","author":"Marso","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R6-14-20210129","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"De Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"R7-14-20210129","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"R8-14-20210129","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R9-14-20210129","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-14-20210129","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":"2009 focused update: ACCF\/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"R12-14-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.20452\/pamw.875","article-title":"Reappraisal of the European guidelines on hypertension management: The European Society of Hypertension Task Force document: A short review","volume":"120","author":"Fagard","year":"2010","journal-title":"Pol Arch Med Wewn"},{"key":"R15-14-20210129","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1523-1755.2004.09201.x","article-title":"Albuminuria, not only a cardiovascular\/renal risk marker, but also a target for treatment?","volume":"66","author":"De Zeeuw","year":"2004","journal-title":"Kidney Int Suppl"},{"key":"R16-14-20210129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"R17-14-20210129","first-page":"S269","article-title":"Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans","volume":"3","author":"Nussberger","year":"1985","journal-title":"J Hypertens Suppl"},{"key":"R18-14-20210129","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00004872-199208000-00015","article-title":"Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response?","volume":"10","author":"Van den Meiracker","year":"1992","journal-title":"J Hypertens"},{"key":"R19-14-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"R20-14-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"R21-14-20210129","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1136\/bmj.294.6588.1651","article-title":"Proteinuria: Value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus","volume":"294","author":"Borch-Johnsen","year":"1987","journal-title":"Br Med J (Clin Res Ed"},{"key":"R22-14-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"R23-14-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"R24-14-20210129","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2337\/dc09-0191","article-title":"Cystatin C, albuminuria, and mortality among older adults with diabetes","volume":"32","author":"De Boer","year":"2009","journal-title":"Diabetes Care"},{"key":"R25-14-20210129","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats","volume":"96","author":"M\u00e9nard","year":"1997","journal-title":"Circulation"},{"key":"R26-14-20210129","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"R27-14-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajh\/hps038","article-title":"Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: A meta-analysis","volume":"26","author":"Susantitaphong","year":"2013","journal-title":"Am J Hypertens"},{"key":"R28-14-20210129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R29-14-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","article-title":"Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis","volume":"24","author":"Jennings","year":"2007","journal-title":"Diabet Med"},{"key":"R30-14-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.ajkd.2012.07.011","article-title":"Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial","volume":"61","author":"Fernandez","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R31-14-20210129","first-page":"151","article-title":"Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy","volume":"51","author":"Tan","year":"2010","journal-title":"Singapore Med J"},{"key":"R32-14-20210129","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"R33-14-20210129","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"R34-14-20210129","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"key":"R35-14-20210129","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"R36-14-20210129","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"R37-14-20210129","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R38-14-20210129","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","article-title":"Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial","volume":"72","author":"Bakris","year":"2007","journal-title":"Kidney Int"},{"key":"R39-14-20210129","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/HJH.0b013e32830508aa","article-title":"Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: The VALERIA trial","volume":"26","author":"Menne","year":"2008","journal-title":"J Hypertens"},{"key":"R40-14-20210129","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.ajkd.2008.03.008","article-title":"Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression","volume":"52","author":"Catapano","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R41-14-20210129","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R42-14-20210129","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"R43-14-20210129","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11886-009-0063-3","article-title":"The current state of RAAS blockade in the treatment of hypertension and proteinuria","volume":"11","author":"Kalaitzidis","year":"2009","journal-title":"Curr Cardiol Rep"},{"key":"R44-14-20210129","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/ajh.2009.138","article-title":"Dual blockade of the renin-angiotensin-aldosterone system: Beyond the ACE inhibitor and angiotensin-II receptor blocker combination","volume":"22","author":"Bomback","year":"2009","journal-title":"Am J Hypertens"},{"key":"R45-14-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/01.HYP.0000047512.58862.A9","article-title":"Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor?","volume":"41","author":"Forclaz","year":"2003","journal-title":"Hypertension"},{"key":"R46-14-20210129","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2008040381","article-title":"Is there added value to adding ARB to ACE inhibitors in the management of CKD?","volume":"20","author":"Cohen","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R47-14-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R48-14-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"R49-14-20210129","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/hr.2013.86","article-title":"Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: A post-hoc analysis (ORIENT-Hypertension)","volume":"36","author":"Imai","year":"2013","journal-title":"Hypertens Res"},{"key":"R50-14-20210129","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"R51-14-20210129","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"R52-14-20210129","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/j.1463-1326.2010.01298.x","article-title":"Beyond ONTARGET: Angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some?","volume":"12","author":"Wong","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"R53-14-20210129","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/eurheartj\/ehq255","article-title":"Of fads, fashion, surrogate endpoints and dual RAS blockade","volume":"31","author":"Messerli","year":"2010","journal-title":"Eur Heart J"},{"key":"R54-14-20210129","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"key":"R55-14-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"R56-14-20210129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R57-14-20210129","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"R58-14-20210129","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R59-14-20210129","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacc.2007.10.027","article-title":"Renin inhibition in hypertension","volume":"51","author":"Gradman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R60-14-20210129","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MNH.0b013e32832e3183","article-title":"Is there a role for direct renin inhibitors in chronic kidney disease?","volume":"18","author":"Peixoto","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R61-14-20210129","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","article-title":"Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria","volume":"32","author":"Persson","year":"2009","journal-title":"Diabetes Care"},{"key":"R62-14-20210129","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"R63-14-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"R64-14-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/HJH.0b013e32835bf7b0","article-title":"Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: Results of the ONTARGET trial","volume":"31","author":"Mann","year":"2013","journal-title":"J Hypertens"},{"key":"R65-14-20210129","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","article-title":"Longitudinal studies on the rate of decline in renal function with age","volume":"33","author":"Lindeman","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"R66-14-20210129","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMc1315504","article-title":"Combined angiotensin inhibition in diabetic nephropathy","volume":"370","author":"Izumi","year":"2014","journal-title":"N Engl J Med"},{"key":"R67-14-20210129","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"R68-14-20210129","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","article-title":"Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study","volume":"16","author":"Schmieder","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R69-14-20210129","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1681\/ASN.2008040416","article-title":"SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease","volume":"20","author":"Burgess","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R70-14-20210129","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s00125-010-1789-6","article-title":"Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: A randomised crossover trial","volume":"53","author":"Persson","year":"2010","journal-title":"Diabetologia"},{"key":"R71-14-20210129","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/HJH.0b013e328332bd61","article-title":"Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria","volume":"28","author":"Weir","year":"2010","journal-title":"J Hypertens"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.172599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T22:51:57Z","timestamp":1748731917000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201601050-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,5]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.172599","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,5]]}}}